Article Details
Retrieved on: 2022-05-12 08:15:23
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
SHANGHAI, May 12, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I ...
Article found on: www.asiaone.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here